Actelion

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Actelion sits in the top decile of US sponsors by registered trial count (#328 of 15,742 sponsors by registered trial count).

63 total trials none currently recruiting 43 completed top decile by trial count

Actelion: 63 sponsored US clinical trials, none currently recruiting.

Actelion sponsors 63 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 43 completed. 34 of these trials are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Arterial Hypertension, with 7 trials.

Top-decile sponsor footprint

Actelion ranks in the top decile of sponsors by registered trial count (#328 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 18/100

43 of 60 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (71.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

63 total, page 2 of 2

COMPLETED Phase 1

Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects

NCT02223832

COMPLETED Phase 3

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension

NCT00667823

TERMINATED

Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)

NCT00706082

COMPLETED Phase 3

Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension

NCT00709098

TERMINATED Phase 3

Iloprost Power Disc-15 in Pulmonary Arterial Hypertension

NCT00723554

COMPLETED Phase 3

Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

NCT00660179

TERMINATED Phase 2

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

NCT00467896

COMPLETED

REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management

NCT00370214

COMPLETED Phase 2

Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis

NCT00109681

COMPLETED Phase 2

Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT00086463

COMPLETED Phase 3

Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

NCT00091715

COMPLETED Phase 4

BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology

NCT00367770

COMPLETED Phase 2

Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis

NCT00071461

← Previous Page 2 of 2

How the Actelion archive is shaped

63 indexed studies, none listed as recruiting (0% open); 43 completed (68%).

Phase mix: 34 late (III/IV) vs 23 early (I/II) (balanced across stages).

Top condition: Pulmonary Arterial Hypertension (7 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Actelion: archived-pipeline peers nationwide

Peers matched on 63 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Actelion sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 020406080 0%5%10%15%20% Total trials Recruiting share ActelionHennepin Healthcare Research InstituteUnited TherapeuticsUniversity of OregonCephalon10xBio22nd Century Group23andMe3-C Institute for Social Development
Actelion sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Actelion sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 63 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Actelion page

63 registered trials is a research-attention snapshot, not an endorsement of Actelion or any single study.

  • None of Actelion's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Pulmonary Arterial Hypertension is the condition Actelion studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pulmonary Arterial Hypertension trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Actelion pipeline card: 63 registered trials from official public datasets.Report a data error.